SCHEMBL208580

SCHEMBL208580

NC(=O)CNC(=O)c1ccc(-c2cc(Cl)c(C[C@@H]3CCN([C@H]4CC[C@H](O)CC4)C3=O)c(Cl)c2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.35
USP5 P45974 5/20 0.33
F2 P00734 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
ST14 Q9Y5Y6 1/20 0.33
ITGB3 P05106 4/20 0.33
ITGA2B P08514 4/20 0.33
PIP5K1C O60331 1/20 0.33
PIK3CA P42336 1/20 0.33
HSD11B1 P28845 1/20 0.33
CTSS P25774 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
BMPR1B O00238 1/20 0.32
BMPR1A P36894 1/20 0.32
TGFBR1 P36897 1/20 0.32
ACVRL1 P37023 1/20 0.32
ACVR1 Q04771 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208578 1.00 PDE4B (0.35) PDE4BUSP5F2PRSS1PRSS2
SCHEMBL210001 0.90 PDE4B (0.37) PDE4BUSP5HSD11B1CTSSMCHR1
SCHEMBL209999 0.90 PDE4B (0.37) PDE4BUSP5HSD11B1CTSSMCHR1
SCHEMBL209204 0.89 PDE4B (0.37) PDE4BUSP5HSD11B1CTSSMCHR1
SCHEMBL209206 0.89 PDE4B (0.37) PDE4BUSP5HSD11B1CTSSMCHR1
SCHEMBL208233 0.85 PDE4B (0.37) PDE4BITGB3ITGA2B
SCHEMBL208579 0.84 HSD11B1 (0.35) PDE4BHSD11B1
SCHEMBL209956 0.84 HSD11B1 (0.45) PDE4BUSP5HSD11B1HDAC6
SCHEMBL210000 0.81 HSD11B1 (0.35) PDE4BHSD11B1SMN1; SMN2
SCHEMBL209301 0.81 HSD11B1 (0.42) PRSS1HSD11B1BMPR1BBMPR1ATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP claimed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US claimed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US claimed
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 PDE4B 1307/4885USP5 1201/4885F2 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.